| Date Initiated by Firm | October 01, 2025 |
| Date Posted | November 17, 2025 |
| Recall Status1 |
Open3, Classified |
| Recall Number | Z-0534-2026 |
| Recall Event ID |
97763 |
| Product Classification |
Enzyme linked immunoabsorbent assay, rubeola IgG - Product Code LJB
|
| Product | Brand Name: ReQuest Measles IgG
Product Name: Rubeola IgG Enzyme Linked Immunoabsorbant Assay
Model/Catalog Number: 01-190
Software Version: N/A
Product Description: Measles IgG tests, performed using ELISA (Enzyme-Linked Immunosorbent Assay) method, used to detect the presence of IgG antibodies against measles virus in a patient's serum or plasma
Component: not a component |
| Code Information |
Lot Code: DI# 00850487007357
Lots affected: L07024 and E03025
|
Recalling Firm/ Manufacturer |
Quest International, Inc. 8127 Nw 29th St Doral FL 33122-1051
|
| For Additional Information Contact | Steve Andrus +1-772-2836540 |
Manufacturer Reason for Recall | Due to distributing the measles IgG IVD without a premarket approved/cleared. |
FDA Determined Cause 2 | No Marketing Application |
| Action | On 10/01/2025, the firm email an "URGENT: Medical Device Recall Measles IgG IFU" letter to customers informing them that the Measles IgG Medical Device is subject to the limitations of exemption from premarket notification (510(k)) under 21 CFR866.9(c)(7) and is subject to the 510(k) premarket requirements prior to being marketed and distributed in the U.S.
Customers are instructed to examine their inventory, discontinue use and quarantine the affected lot and review the updated Instruction for Use (IFU) and ensure all relevant personnel are informed of the changes. The previous version of the IFU should be replace with the updated version, Revision 9.
The updated IFU (Revision 9) can also be requested by contacting Customer Support team at jopain@awartech.com.
Awareness Technology, Inc. will be revising the intended use of the product to be only for qualitative detection of human IgG antibodies to measles virus in human serum by enzyme immunoassay. The company will also be removing language in the Instructions for Use (IFU) that could be interpreted as determining immune status, statements regarding paired sera for demonstrating seroconversion or significant rise in antibody levels, and any reference to semi-quantitative procedures.
The updated IFU (Revision 9) will be included in all product shipments starting 10/01/2025.
For questions or assistance, contact Customer Service at jcopain@awaretech.com. |
| Distribution | All products were distributed in the United States. (Utah, Washington). |
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
|